172 related articles for article (PubMed ID: 35395182)
1. Successful organoid-mediated generation of iPSC-derived CAR-T cells.
Kaneko S
Cell Stem Cell; 2022 Apr; 29(4):493-495. PubMed ID: 35395182
[TBL] [Abstract][Full Text] [Related]
2. 3D-organoid culture supports differentiation of human CAR
Wang Z; McWilliams-Koeppen HP; Reza H; Ostberg JR; Chen W; Wang X; Huynh C; Vyas V; Chang WC; Starr R; Wagner JR; Aguilar B; Yang X; Wu X; Wang J; Chen W; Koelker-Wolfe E; Seet CS; Montel-Hagen A; Crooks GM; Forman SJ; Brown CE
Cell Stem Cell; 2022 Apr; 29(4):515-527.e8. PubMed ID: 35278370
[TBL] [Abstract][Full Text] [Related]
3. Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor T Cells: The Intersection of Stem Cells and Immunotherapy.
Lahimchi MR; Maroufi F; Maali A
Cell Reprogram; 2023 Oct; 25(5):195-211. PubMed ID: 37782910
[TBL] [Abstract][Full Text] [Related]
4. Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products.
Sadeqi Nezhad M; Abdollahpour-Alitappeh M; Rezaei B; Yazdanifar M; Seifalian AM
Pharm Res; 2021 Jun; 38(6):931-945. PubMed ID: 34114161
[TBL] [Abstract][Full Text] [Related]
5. Strength of CAR signaling determines T cell versus ILC differentiation from pluripotent stem cells.
Li S; Wang CS; Montel-Hagen A; Chen HC; Lopez S; Zhou O; Dai K; Tsai S; Satyadi W; Botero C; Wong C; Casero D; Crooks GM; Seet CS
Cell Rep; 2023 Mar; 42(3):112241. PubMed ID: 36906850
[TBL] [Abstract][Full Text] [Related]
6. Scalable generation of functional human iPSC-derived CAR-macrophages that efficiently eradicate CD19-positive leukemia.
Abdin SM; Paasch D; Kloos A; Oliveira MC; Jang MS; Ackermann M; Stamopoulou A; Mroch PJ; Falk CS; von Kaisenberg CS; Schambach A; Heuser M; Moritz T; Hansen G; Morgan M; Lachmann N
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38135346
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Differentiation of T Cell: From CAR-Modified T-iPSC.
Ueda T; Kaneko S
Methods Mol Biol; 2019; 2048():85-91. PubMed ID: 31396933
[TBL] [Abstract][Full Text] [Related]
8. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
[TBL] [Abstract][Full Text] [Related]
9. CD19 chimeric antigen receptor-redirected T cells combined with epidermal growth factor receptor pathway substrate 8 peptide-derived dendritic cell vaccine in leukemia.
Wu M; Zhang L; Zhang H; Ning J; Tu S; He Y; Li Y
Cytotherapy; 2019 Jun; 21(6):659-670. PubMed ID: 31031152
[TBL] [Abstract][Full Text] [Related]
10. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
11. EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity.
Jing R; Scarfo I; Najia MA; Lummertz da Rocha E; Han A; Sanborn M; Bingham T; Kubaczka C; Jha DK; Falchetti M; Schlaeger TM; North TE; Maus MV; Daley GQ
Cell Stem Cell; 2022 Aug; 29(8):1181-1196.e6. PubMed ID: 35931029
[TBL] [Abstract][Full Text] [Related]
12. 3D model for CAR-mediated cytotoxicity using patient-derived colorectal cancer organoids.
Schnalzger TE; de Groot MH; Zhang C; Mosa MH; Michels BE; Röder J; Darvishi T; Wels WS; Farin HF
EMBO J; 2019 Jun; 38(12):. PubMed ID: 31036555
[TBL] [Abstract][Full Text] [Related]
13.
Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
Front Immunol; 2022; 13():770132. PubMed ID: 35154098
[TBL] [Abstract][Full Text] [Related]
14. In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
Ramos CA; Rouce R; Robertson CS; Reyna A; Narala N; Vyas G; Mehta B; Zhang H; Dakhova O; Carrum G; Kamble RT; Gee AP; Mei Z; Wu MF; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Savoldo B; Dotti G
Mol Ther; 2018 Dec; 26(12):2727-2737. PubMed ID: 30309819
[TBL] [Abstract][Full Text] [Related]
15. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
[TBL] [Abstract][Full Text] [Related]
16. A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells.
Kueberuwa G; Zheng W; Kalaitsidou M; Gilham DE; Hawkins RE
J Vis Exp; 2018 Oct; (140):. PubMed ID: 30394400
[TBL] [Abstract][Full Text] [Related]
17. Generating universal chimeric antigen receptor expressing cell products from induced pluripotent stem cells: beyond the autologous CAR-T cells.
Deng X; Zhou J; Cao Y
Chin Med J (Engl); 2023 Jan; 136(2):127-137. PubMed ID: 36806264
[TBL] [Abstract][Full Text] [Related]
18. Activation and degranulation of CAR-T cells using engineered antigen-presenting cell surfaces.
Dirar Q; Russell T; Liu L; Ahn S; Dotti G; Aravamudhan S; Conforti L; Yun Y
PLoS One; 2020; 15(9):e0238819. PubMed ID: 32976541
[TBL] [Abstract][Full Text] [Related]
19. CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile.
Magalhaes I; Kalland I; Kochenderfer JN; Österborg A; Uhlin M; Mattsson J
J Immunother; 2018; 41(2):73-83. PubMed ID: 29315094
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of lymphoblastic leukemia with CD19-specific modified chimeric antigen receptor T cells].
Li HH; Zhu P; Wu XQ; Liu YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1753-6. PubMed ID: 25543510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]